Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Quartet to investigate GPCR drug target
September 2013
SHARING OPTIONS:

COPENHAGEN, Denmark—Nuevolution AS has announced the establishment of a scientific collaboration with Duke University, the Howard Hughes Medical Institute and Lexicon Pharmaceuticals Inc. to investigate the biological mechanism of action of a GPCR drug target. Under this collaboration, Nuevolution will be providing access to its proprietary Chemetics technology, with both Nuevolution and Lexicon providing access to selected chemical libraries created with Chemetics technology.
 
"We have used the Chemetics technology successfully to identify novel chemotypes for our internal programs and are enthusiastic about exploring the utility of our DNA-tagged libraries of diverse chemical compounds in the screening of GPCRs. We look forward to working with Nuevolution and Dr. Lefkowitz's team at Duke University on this project," said Dr. Brian P. Zambrowicz, executive vice president and chief scientific officer of Lexicon.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.